Using phages to deliver genes for treating aggressive breast cancer
Phage-based therapeutic gene delivery targeting multiple compartments in solid tumors
This study is testing a new treatment for triple-negative breast cancer using special viruses that can deliver helpful genes directly to the tumor, with the hope of making the treatment work better and improving outcomes for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10986635 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer with limited treatment options. The approach involves using bacteriophages, which are viruses that specifically target bacteria, to deliver therapeutic genes directly to the tumor cells. By targeting the tumor microenvironment and the immune cells within it, the research aims to enhance the effectiveness of treatment and potentially improve patient outcomes. The study will explore how these phage-based therapies can overcome the challenges posed by the tumor's immune evasion mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who do not have a diagnosis of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer, potentially improving survival rates.
How similar studies have performed: While the use of phage-based therapies is a novel approach in this context, similar strategies have shown promise in other areas of cancer treatment.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Pasqualini, Renata — Rutgers Biomedical and Health Sciences
- Study coordinator: Pasqualini, Renata
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.